LAS VEGAS--(BUSINESS WIRE)--Sept. 7, 2006--CardioVascular BioTherapeutics, Inc. (OTCBB:CVBT) today announced it has signed a master service agreement with leading global clinical research organization (CRO) Kendle (NASDAQ: KNDL). Kendle will support CVBT in its Phase II clinical trial ensuring that the protocol and study adhere to FDA regulatory requirements. Kendle has worked with CVBT to finalize the protocol that will be submitted to the FDA. The clinical trial is evaluating CVBT's drug candidate, with Cardio Vascu-Grow(TM) as its active ingredient, that is injected into no-option heart patients to stimulate the growth of new blood vessels, a process called angiogenesis.
